Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13534235 | 0.83 | CHRNB2 (0.47) | HTR2CDRD2DRD3CHRNA7DRD1 | |
| SCHEMBL9749054 | 0.83 | LMNA (0.50) | HTR2CCYP19A1LMNAHSD17B10SRD5A1 | |
| SCHEMBL30715514 | 0.83 | CYP19A1 (0.48) | HTR2CCYP19A1LMNAHSD17B10SRD5A1 | |
| SCHEMBL30715515 | 0.83 | CYP19A1 (0.48) | HTR2CCYP19A1LMNAHSD17B10SRD5A1 | |
| SCHEMBL9749057 | 0.83 | LMNA (0.50) | HTR2CCYP19A1LMNAHSD17B10SRD5A1 | |
| SCHEMBL4140163 | 0.83 | LMNA (0.50) | HTR2CCYP19A1LMNAHSD17B10SRD5A1 | |
| SCHEMBL607389 | 0.81 | CYP19A1 (0.52) | HTR2CCYP19A1LMNAHSD17B10SRD5A1 | |
| SCHEMBL16944438 | 0.80 | HTR2C (0.64) | HTR2CCYP19A1LMNASRD5A1DRD2 | |
| SCHEMBL8068811 | 0.80 | HTR2C (0.64) | HTR2CCYP19A1LMNASRD5A1DRD2 | |
| SCHEMBL31525384 | 0.80 | HTR2C (0.64) | HTR2CCYP19A1LMNASRD5A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963292-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1963292-A2 | ORGANIC COMPOUNDS | Novartis Pharma AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067615-A2 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | HTR2C 2338/4885CYP19A1 1316/4885LMNA 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.